Xiao X, Li J, Tsao Y P, Dressman D, Hoffman E P, Watchko J F
Department of Molecular Genetics and Biochemistry, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15261, USA. xiaox+@pitt.edu
J Virol. 2000 Feb;74(3):1436-42. doi: 10.1128/jvi.74.3.1436-1442.2000.
Limb girdle muscular dystrophy (LGMD) 2F is caused by mutations in the delta-sarcoglycan (SG) gene. Previously, we have shown successful application of a recombinant adeno-associated virus (AAV) vector for genetic and biochemical rescue in the Bio14.6 hamster, a homologous animal model for LGMD 2F (J. Li et al., Gene Ther. 6:74-82, 1999). In this report, we show efficient and long-term delta-SG expression accompanied by nearly complete recovery of physiological function deficits after a single-dose AAV vector injection into the tibialis anterior muscle of the dystrophic hamsters. AAV vector treatment led to more than 97% recovery in muscle strength for both the specific twitch force and the specific tetanic force, when compared to the age-matched control. Vector treatment also prevented pathological muscle hypertrophy and resulted in normal muscle weight and size. Finally, vector-treated muscle showed substantial improvement of the histopathology. This is the first report of successful functional rescue of an entire muscle after AAV-mediated gene delivery. This report also demonstrates the feasibility of in vivo gene therapy for LGMD patients by using AAV vectors.
肢带型肌营养不良症(LGMD)2F是由δ-肌聚糖(SG)基因突变引起的。此前,我们已证明重组腺相关病毒(AAV)载体在Bio14.6仓鼠(LGMD 2F的同源动物模型)中用于基因和生化拯救的成功应用(J. Li等人,《基因治疗》6:74 - 82,1999)。在本报告中,我们展示了在向营养不良仓鼠的胫前肌单次注射AAV载体后,δ-SG的高效长期表达以及生理功能缺陷几乎完全恢复。与年龄匹配的对照相比,AAV载体治疗使特定抽搐力和特定强直力的肌肉力量恢复超过97%。载体治疗还防止了病理性肌肉肥大,并使肌肉重量和大小恢复正常。最后,接受载体治疗的肌肉组织病理学有显著改善。这是首次报道AAV介导的基因传递后整个肌肉成功实现功能拯救。本报告还证明了使用AAV载体对LGMD患者进行体内基因治疗的可行性。